Aurobindo Pharma has received final approval from USFDA to manufacture and market Didanosine Delayed Release (enteric-coated) capsules 125mg, 200mg, 250mg and 400mg.
Didanosine Delayed Release capsules is the generic version of Bristol Myer Squibb's Videx EC (Didanosine) Delayed-release capsules, 125mg, 200mg, 250mg and 400mg and is indicated for the treatment of HIV-1 infections in adults. This is Aurobindo's 78th ANDA approval from the USFDA.
The company made this announcement during the trading hours today, 25 September 2008.
NSE tips
No comments:
Post a Comment